169 related articles for article (PubMed ID: 23956056)
1. Overexpression of asparagine synthetase and matrix metalloproteinase 19 confers cisplatin sensitivity in nasopharyngeal carcinoma cells.
Liu RY; Dong Z; Liu J; Zhou L; Huang W; Khoo SK; Zhang Z; Petillo D; Teh BT; Qian CN; Zhang JT
Mol Cancer Ther; 2013 Oct; 12(10):2157-66. PubMed ID: 23956056
[TBL] [Abstract][Full Text] [Related]
2. BST2 confers cisplatin resistance via NF-κB signaling in nasopharyngeal cancer.
Kuang CM; Fu X; Hua YJ; Shuai WD; Ye ZH; Li Y; Peng QH; Li YZ; Chen S; Qian CN; Huang W; Liu RY
Cell Death Dis; 2017 Jun; 8(6):e2874. PubMed ID: 28617432
[TBL] [Abstract][Full Text] [Related]
3. Role of eIF3a in regulating cisplatin sensitivity and in translational control of nucleotide excision repair of nasopharyngeal carcinoma.
Liu RY; Dong Z; Liu J; Yin JY; Zhou L; Wu X; Yang Y; Mo W; Huang W; Khoo SK; Chen J; Petillo D; Teh BT; Qian CN; Zhang JT
Oncogene; 2011 Dec; 30(48):4814-23. PubMed ID: 21625209
[TBL] [Abstract][Full Text] [Related]
4. Metformin reverses the drug resistance of cisplatin in irradiated CNE-1 human nasopharyngeal carcinoma cells through PECAM-1 mediated MRPs down-regulation.
Sun Y; Chen X; Zhou Y; Qiu S; Wu Y; Xie M; Zhu G; Liang S; Li H; Zhou D; Ju Z; Wang F; Han F; Wang Z; Wang R
Int J Med Sci; 2020; 17(16):2416-2426. PubMed ID: 33029084
[No Abstract] [Full Text] [Related]
5. MiR-34c downregulation leads to SOX4 overexpression and cisplatin resistance in nasopharyngeal carcinoma.
Bissey PA; Teng M; Law JH; Shi W; Bruce JP; Petit V; Tsao SW; Yip KW; Liu FF
BMC Cancer; 2020 Jun; 20(1):597. PubMed ID: 32586280
[TBL] [Abstract][Full Text] [Related]
6. High expression of XPA confers poor prognosis for nasopharyngeal carcinoma patients treated with platinum-based chemoradiotherapy.
Fu X; Hu J; Han HY; Hua YJ; Zhou L; Shuai WD; Du WY; Kuang CM; Chen S; Huang W; Liu RY
Oncotarget; 2015 Sep; 6(29):28478-90. PubMed ID: 26156020
[TBL] [Abstract][Full Text] [Related]
7. Catalytic activity of Matrix metalloproteinase-19 is essential for tumor suppressor and anti-angiogenic activities in nasopharyngeal carcinoma.
Chan KC; Ko JM; Lung HL; Sedlacek R; Zhang ZF; Luo DZ; Feng ZB; Chen S; Chen H; Chan KW; Tsao SW; Chua DT; Zabarovsky ER; Stanbridge EJ; Lung ML
Int J Cancer; 2011 Oct; 129(8):1826-37. PubMed ID: 21165953
[TBL] [Abstract][Full Text] [Related]
8. Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways.
Pan Y; Zhang Q; Atsaves V; Yang H; Claret FX
Oncogene; 2013 May; 32(22):2756-66. PubMed ID: 22797071
[TBL] [Abstract][Full Text] [Related]
9. Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin.
Cui H; Darmanin S; Natsuisaka M; Kondo T; Asaka M; Shindoh M; Higashino F; Hamuro J; Okada F; Kobayashi M; Nakagawa K; Koide H; Kobayashi M
Cancer Res; 2007 Apr; 67(7):3345-55. PubMed ID: 17409444
[TBL] [Abstract][Full Text] [Related]
10. Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1.
Gao J; Shao Z; Yan M; Fu T; Zhang L; Yan Y
Cancer Biomark; 2018; 22(4):641-648. PubMed ID: 29914005
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of excision repair cross- complementation group 1 expression in locoregionally advanced nasopharyngeal carcinoma receiving cisplatin-based concurrent chemoradiotherapy.
Wang D; Zhou J; Zheng J; Zhang J; Chen Y; Li W; Wang R
Cancer Biomark; 2018; 21(4):875-881. PubMed ID: 29439312
[TBL] [Abstract][Full Text] [Related]
12. MiR-183 overexpression inhibits tumorigenesis and enhances DDP-induced cytotoxicity by targeting MTA1 in nasopharyngeal carcinoma.
Wang G; Wang S; Li C
Tumour Biol; 2017 Jun; 39(6):1010428317703825. PubMed ID: 28631568
[TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial.
Lv X; Cao X; Xia WX; Liu KY; Qiang MY; Guo L; Qian CN; Cao KJ; Mo HY; Li XM; Li ZH; Han F; He YX; Liu YM; Wu SX; Bai YR; Ke LR; Qiu WZ; Liang H; Liu GY; Miao JJ; Li WZ; Lv SH; Chen X; Zhao C; Xiang YQ; Guo X
Lancet Oncol; 2021 May; 22(5):716-726. PubMed ID: 33857411
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of asparagine synthetase (ASNS) suppresses cell proliferation and inhibits tumor growth in gastric cancer cells.
Yu Q; Wang X; Wang L; Zheng J; Wang J; Wang B
Scand J Gastroenterol; 2016 Oct; 51(10):1220-6. PubMed ID: 27251594
[TBL] [Abstract][Full Text] [Related]
15. Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy.
Shen C; Chen L; Fu J; Lin H
J Cancer Res Ther; 2016 Oct; 12(Supplement):72-75. PubMed ID: 27721259
[TBL] [Abstract][Full Text] [Related]
16. FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein.
Song Y; Zhou X; Bai W; Ma X
Tumour Biol; 2015 Jun; 36(6):4197-202. PubMed ID: 25586348
[TBL] [Abstract][Full Text] [Related]
17. Correlation between ERCC1 expression and concurrent chemotherapy and radiotherapy in patients with locally advanced nasopharyngeal cancer.
Liang R; Lin Y; Liu ZH; Liao XL; Yuan CL; Liao SN; Li YQ
Genet Mol Res; 2015 May; 14(2):5804-11. PubMed ID: 26125779
[TBL] [Abstract][Full Text] [Related]
18. A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma.
Lei Y; Li YQ; Jiang W; Hong XH; Ge WX; Zhang Y; Hu WH; Wang YQ; Liang YL; Li JY; Cho WCS; Yun JP; Zeng J; Chen JW; Liu LZ; Li L; Chen L; Xie FY; Li WF; Mao YP; Liu X; Chen YP; Tang LL; Sun Y; Liu N; Ma J
J Natl Cancer Inst; 2021 Apr; 113(4):471-480. PubMed ID: 33094348
[TBL] [Abstract][Full Text] [Related]
19. High NEK2 confers to poor prognosis and contributes to cisplatin-based chemotherapy resistance in nasopharyngeal carcinoma.
Xu H; Zeng L; Guan Y; Feng X; Zhu Y; Lu Y; Shi C; Chen S; Xia J; Guo J; Kuang C; Li W; Jin F; Zhou W
J Cell Biochem; 2019 Mar; 120(3):3547-3558. PubMed ID: 30295336
[TBL] [Abstract][Full Text] [Related]
20. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
